



























































































































































































FDG腫瘍集積性 Differential uptake ratio(DUR)
投与後日数
マイトマイシン投与群 シスプラチン投与群 アドリアマイシン投与群  コントロール群 
1.24±0.06      1.26±0.06      1.43±0.221.44±0.32１
1.26±0.14      1.26±0.14      1.27±0.371.36±0.30３
1.01±0.16      1.01±0.16      1.20±0.451.44±0.40５
0.93±0.21*   0.93±0.21*   1.26±0.231.35±0.32７
0.97±0.22**0.97±0.22**1.32±0.221.41±0.2110









































































DUR=（組織Radioisotope counts / 組織重量）÷（投
与量 counts / 組織重量）














































PR0.83  4  膵癌肝転移 
PR0.93.43.8術後胃癌肝転移 
SD0.92.83  肝癌 
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The Role of Positron Emission Tomography on Cancer 
Chemotherapy
　It is the most important to evaluate the efficacy of anti-cancer agents rapidly in 
planning the treatment for the individual patient. The development of positron 
emission tomography (PET) has made it possible to study the metabolism of cancer 
tissues visually and evaluate the efficacy of cancer chemotherapy more rapidly and 
exactly than morphological examinations. 2-deoxy-2-[18F]fluoro-D-glucose (FDG) is a 
tracer for glucose metabolism and widely used in cancer diagnosis. Some reports showed 
that FDG was very useful for the early evaluation of cancer chemotherapy and the 
prediction of prognosis in patients with breast cancer, lymphoma, colonic cancer and 
esophageal cancer. From this point of view, tracers for nucleic and amino acid 
metabolisms are also promising. PET will play the more and more important role on the 
evaluation of efficacy for cancer chemotherapy.  
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